Navigation Links
Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
Date:11/6/2012

RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:30 pm ET on Tuesday, November 13, 2012, at the Lazard Capital Markets 9th Annual Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
2. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
4. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
5. Sangamo BioSciences Reports First Quarter 2012 Financial Results
6. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
9. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a leading Silicon Valley, ... Industries, announces the new Model 800E front and backside, semi-automatic mask aligner system. ... aligners. OAI has already received and installed several orders for the ...
(Date:8/17/2017)... CA (PRWEB) , ... August 17, 2017 , ... ... for cancer research and personalized medicine, today announced the launch of a new ... City, Missouri. The study’s goal is to evaluate the potential for early detection ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Electrospraying line of nanofiber and nanoparticle fabrication instruments from Bioinicia. ... to fully automated pilot plants and equipment for industrial manufacturing. All equipment ...
(Date:8/16/2017)... ... ... While art and science are often thought of as two completely separate modes ... Mesh Is Also a Snare, a group exhibition presented by the Philadelphia-based artist collective ... on August 17 and run through September 30. An opening reception will be held ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):